{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:12:54Z","timestamp":1792732374020,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaad.2018.07.051","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T05:25:26Z","timestamp":1533533126000},"page":"1165-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Immune checkpoint inhibitors and the development of granulomatous reactions"],"prefix":"10.1016","volume":"81","author":[{"given":"Christine M.","family":"Cornejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jaad.2018.07.051_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.051_bib2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.jaad.2018.07.051_bib3","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2018.07.051_bib5","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE). Available at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed December 17, 2017."},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.051_bib7","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/jdv.14781","article-title":"Programmed cell death 1 blockade-induced cutaneous sarcoid-like epithelioid granulomas in advanced melanoma: a case report","volume":"32","author":"Ogawa","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2018.07.051_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition","volume":"2016","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2018.07.051_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.051_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"suppl","key":"10.1016\/j.jaad.2018.07.051_bib15","doi-asserted-by":"crossref","first-page":"A724","DOI":"10.1016\/j.chest.2017.08.753","article-title":"Ipilimumab lung toxicity","volume":"152","author":"Oommen","year":"2017","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.051_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib17","doi-asserted-by":"crossref","first-page":"e1068","DOI":"10.1097\/MJT.0000000000000266","article-title":"Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma","volume":"23","author":"Toumeh","year":"2016","journal-title":"Am J Ther"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.revmed.2017.11.008","article-title":"Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission","volume":"39","author":"Yatim","year":"2018","journal-title":"Rev Med Interne"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.051_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib20","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/dth.12380","article-title":"Cutaneous sarcoidosis in a melanoma patient under ipilimumab therapy","volume":"29","author":"Martinez Leborans","year":"2016","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","article-title":"Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient","volume":"218","author":"Eckert","year":"2009","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000213245","article-title":"Sarcoidosis and melanoma: a referral center study of 1,199 cases","volume":"219","author":"Seve","year":"2009","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib25","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JOP.2017.027383","article-title":"Pembrolizumab-related sarcoid-like reaction presenting as reactivation of quiescent scars","volume":"14","author":"McKenna","year":"2018","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib27","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(18)30252-3","article-title":"Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases","volume":"19","author":"Jespersen","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.051_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","article-title":"Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum","volume":"153","author":"Burillo-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-018-0372-4","article-title":"Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment","volume":"6","author":"Paolini","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.051_bib30","doi-asserted-by":"crossref","first-page":"e954506","DOI":"10.4161\/21624011.2014.954506","article-title":"Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab","volume":"3","author":"Andersen","year":"2014","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1513\/AnnalsATS.201611-863LE","article-title":"Sarcoidosis-like Granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy","volume":"14","author":"Balestra","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaad.2018.07.051_bib32","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.crad.2017.06.047","article-title":"Pembrolizumab induced sarcoidosis during the treatment of metastatic malignant melanoma: a series of three patients","volume":"72","author":"Cheshire","year":"2017","journal-title":"Clin Radiol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib33","doi-asserted-by":"crossref","first-page":"W183","DOI":"10.2214\/AJR.17.19144","article-title":"A sarcoidlike reaction mimicking metastatic malignancy in a patient with melanoma treated with pembrolizumab","volume":"210","author":"Wesselius","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jaad.2018.07.051_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2018.07.051_bib36","first-page":"126","article-title":"Pembrolizumab reactivates pulmonary granulomatosis","volume":"22","author":"Al-Dliw","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib37","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1097\/MJT.0000000000000545","article-title":"Ipilimumab-induced sarcoidosis and thyroiditis","volume":"25","author":"Nandavaram","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaad.2018.07.051_bib38","unstructured":"Feneran A, Kazakov, J, Honda K, Koon H, and Gerstenblith M. Sarcoidosis-like granulomatous inflammation induced by pembrolizumab (abstract). Society for Melanoma Research 2016 Congress. Pigment Cell & Melanoma Research. Hoboken, NJ: John Wiley & Sons LTD; 2017."},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib39","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"issue":"17","key":"10.1016\/j.jaad.2018.07.051_bib41","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib42","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission","volume":"30","author":"Vogel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudie","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.07.051_bib45","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/annonc\/mdw256","article-title":"Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib46","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1159\/000484596","article-title":"Pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report","volume":"10","author":"Fakhri","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jaad.2018.07.051_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib48","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 Antibody Therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"Am J Roentgenol"},{"issue":"11","key":"10.1016\/j.jaad.2018.07.051_bib49","first-page":"857","article-title":"Induction of muscular sarcoidosis in a metastatic melanoma patient treated with ipilimumab","volume":"10","author":"Plachouri","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0b013e31828da691","article-title":"Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET\/CT interpretation","volume":"39","author":"Gilardi","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0897190017699762","article-title":"Case Report of ipilimumab-induced diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis","volume":"31","author":"Arellano","year":"2018","journal-title":"J Pharm Pract"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000480155","article-title":"EBUS-TBNA Can distinguish sarcoid-like side effect of nivolumab treatment from tumor progression in non-small cell lung cancer","volume":"94","author":"Lainez","year":"2017","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.051_bib53","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000001758","article-title":"Nivolumab-induced development of pulmonary sarcoidosis in renal cell carcinoma","volume":"42","author":"Zhang","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"26","key":"10.1016\/j.jaad.2018.07.051_bib54","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2017.06.014","article-title":"Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy","volume":"4","author":"Jiang","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.051_bib56","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/cup.13044","article-title":"Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy-report of 2 patients","volume":"44","author":"Tetzlaff","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib57","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1111\/jdv.14617","article-title":"Granuloma annulare associated with immune checkpoint inhibitors","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"256","key":"10.1016\/j.jaad.2018.07.051_bib58","article-title":"Granuloma annulare in the setting of ipilimumab therapy","volume":"6","author":"Haselden","year":"2015","journal-title":"J Clin Exp Dermatol Res"},{"key":"10.1016\/j.jaad.2018.07.051_bib59","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/cup.13267","article-title":"Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis)","volume":"45","author":"Kubicki","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijd.13540","article-title":"Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib61","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/cup.13133","article-title":"Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer","volume":"45","author":"Diaz-Perez","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/bjd.14674","article-title":"Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection","volume":"175","author":"Bisschop","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.051_bib65","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.jaad.2018.07.051_bib66","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.051_bib67","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics","volume":"305","author":"Iannuzzi","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-0030-1262212","article-title":"Cutaneous sarcoidosis","volume":"31","author":"Marchell","year":"2010","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib70","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JCO.2013.49.7735","article-title":"Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab","volume":"33","author":"Luke","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jaad.2018.07.051_bib71","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.07.051_bib72","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-015-0265-8","article-title":"Impaired survival of regulatory T cells in pulmonary sarcoidosis","volume":"16","author":"Broos","year":"2015","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200905-0696OC","article-title":"Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2","volume":"181","author":"Chen","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib74","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.051_bib76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cei.12403","article-title":"Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren's syndrome","volume":"178","author":"Ostadkarampour","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm1694","article-title":"Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion","volume":"14","author":"Coury","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib78","first-page":"737","article-title":"Multinucleated giant cells generation induced by interferon-gamma. Changes in the expression and distribution of the intercellular adhesion molecule-1 during macrophages fusion and multinucleated giant cell formation","volume":"71","author":"Fais","year":"1994","journal-title":"Lab Invest"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.051_bib79","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","article-title":"Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung","volume":"184","author":"Okamoto Yoshida","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.jaad.2018.07.051_bib80","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-gamma-producing t-helper 17.1 cells are increased in sarcoidosis and are more prevalent than t-helper type 1 cells","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.051_bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","article-title":"Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis","volume":"51","author":"Ten Berge","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib84","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1519","article-title":"Sarcoidosis is associated with a truncating splice site mutation in BTNL2","volume":"37","author":"Valentonyte","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaad.2018.07.051_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.051_bib86","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"D'Addio","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2018.07.051_bib87","article-title":"The altered PD-1\/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg\/Th17 imbalance in pre-eclampsia","author":"Zhang","year":"2017","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.051_bib88","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.051_bib89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1165\/rcmb.2016-0037OC","article-title":"Programmed death-1 inhibition of phosphatidylinositol 3-kinase\/AKT\/mechanistic target of rapamycin signaling impairs sarcoidosis CD4(+) T\u00a0cell proliferation","volume":"56","author":"Celada","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.051_bib90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaad.2018.07.051_bib91","doi-asserted-by":"crossref","first-page":"3642832","DOI":"10.1155\/2017\/3642832","article-title":"Local and Systemic CD4(+) T Cell exhaustion reverses with clinical resolution of pulmonary sarcoidosis","volume":"2017","author":"Hawkins","year":"2017","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.051_bib92","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.jaad.2018.07.051_bib93","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1202891","article-title":"Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis","volume":"190","author":"Oswald-Richter","year":"2013","journal-title":"J Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218323557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218323557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:53Z","timestamp":1759272713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218323557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0190962218323557"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.051","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors and the development of granulomatous reactions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}